Bone marrow/bone pre-metastatic niche for breast cancer cells colonization: The role of mesenchymal stromal cells

Sanmartin, María Cecilia; Borzone, Francisco Raúl; Giorello, María Belén; Pacienza, Natalia; Yannarelli, Gustavo; Chasseing, Norma Alejandra

doi:10.1016/j.critrevonc.2021.103416

Cited by 26 publications

(22 citation statements)

References 178 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSC-exos contain a variety of molecules and factors that support tumor growth in vivo, participate in tumor cells acquiring anti-apoptosis and migration ability, and stimulate angiogenesis, thus promote the formation of PMN [ 148 , 149 ]. In Sanmartin’s review, it is systematically reported that MSCs and their EVs play a significant role in BM/bone PMN establishment for BC cell colonization [ 150 ]. However, there are rare studies on MSC-EVs roles in the formation of PMN in other organs of BC.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Pleiotropic Impacts on Breast Cancer Occurrence, Development, and Therapy

Guo

Zhai

et al. 2022

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most devastating cancers, with high morbidity and mortality, among the female population worldwide. In BC, mesenchymal stem cells (MSCs), as pluripotent stromal stem cells, play a significant role in TME formation and tumor progression. Recently, an increasing number of studies have demonstrated that extracellular vesicles (EVs) are essential for the crosstalk between MSCs and BC cells. MSC-derived EVs (MSC-EVs) can deliver a diversity of molecules, including lipids, proteins, and nucleic acids, etc., to target cells, and produce corresponding effects. Studies have demonstrated that MSC-EVs exert both inhibitory and promotive effects in different situations and different stages of BC. Meanwhile, MSC-EVs provide novel therapeutic options for BC, such as EVs as carriers for drug delivery. Therefore, in this review, we summarize the role of MSC-EVs in BC progression and application in clinical treatment, in the hope of providing a basis for further research.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Pleiotropic Impacts on Breast Cancer Occurrence, Development, and Therapy

Guo

Zhai

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…On the one hand, a considerable amount of evidence supports the fact that BM-MSCs can migrate to primary tumors where the microenvironment educates them to become pro-tumoral, either as tumor-associated MSCs, or differentiated into tumor-associated fibroblasts as well ( Hill et al, 2017 ; Giorello et al, 2021 ). In this way, BM-MSCs can promote tumor growth, immunosuppression, inflammation, drug resistance, angiogenesis, invasion and metastasis, and may even promote the establishment of pre-metastatic niches in distant organs ( Gao et al, 2018 ; Pietrovito et al, 2018 ; Xu et al, 2018 ; Sanmartin et al, 2021 ). On the other hand, some studies showed that MSCs could exert inhibitory effects on tumor cells.…”

Section: General Characteristics Of Mesenchymal Stem/stromal Cells An...mentioning

confidence: 99%

“…This evidence supports the potential use of engineered MSC-derived EVs as a strategy for inhibiting the initial steps of the metastatic cascade. Finally, as we previously summarized in a previous review, there are some emerging pre-clinical strategies for targeting the establishment of the pre-metastatic niche (PMN) ( Sanmartin et al, 2021 ). Although none of these mentioned therapeutic approaches consist of the utilization of MSC-derived EVs, these nanovesicles could be tested for the delivery of drugs that aim to target the PMN.…”

Section: Pre-clinical and Clinical Data In Cancermentioning

confidence: 99%

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

Sanmartin

Borzone

Giorello

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cancer is the second leading cause of death worldwide, with 10.0 million cancer deaths in 2020. Despite advances in targeted therapies, some pharmacological drawbacks associated with anticancer chemo and immunotherapeutic agents include high toxicities, low bioavailability, and drug resistance. In recent years, extracellular vesicles emerged as a new promising platform for drug delivery, with the advantage of their inherent biocompatibility and specific targeting compared to artificial nanocarriers, such as liposomes. Particularly, mesenchymal stem/stromal cells were proposed as a source of extracellular vesicles for cancer therapy because of their intrinsic properties: high in vitro self-renewal and proliferation, regenerative and immunomodulatory capacities, and secretion of extracellular vesicles that mediate most of their paracrine functions. Moreover, extracellular vesicles are static and safer in comparison with mesenchymal stem/stromal cells, which can undergo genetic/epigenetic or phenotypic changes after their administration to patients. In this review, we summarize currently reported information regarding mesenchymal stem/stromal cell-derived extracellular vesicles, their proper isolation and purification techniques - from either naive or engineered mesenchymal stem/stromal cells - for their application in cancer therapy, as well as available downstream modification methods to improve their therapeutic properties. Additionally, we discuss the challenges associated with extracellular vesicles for cancer therapy, and we review some preclinical and clinical data available in the literature.

show abstract

“…Studies have shown that macrophages are one of the key determinants of PMN formation. Tissue-resident TAMs, such as osteoclasts and alveolar macrophages, are involved in PMN formation ( 91 , 92 ). What’re more, soluble mediators such as CSF-1, VEGF, TGF-α, and exosomes and tissue inhibitors of metallopeptidase (TIMP) that are involved in the recruitment of TAMs can also mobilize TAMs to aggregate in PMNs ( 92 ).…”

Section: The Roles Of Tams In Pulmonary Metastatic Melanomamentioning

confidence: 99%

The role of tumor-associated macrophages and soluble mediators in pulmonary metastatic melanoma

Xiong

Stoeger

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Skin malignant melanoma is a highly aggressive skin tumor, which is also a major cause of skin cancer-related mortality. It can spread from a relatively small primary tumor and metastasize to multiple locations, including lymph nodes, lungs, liver, bone, and brain. What’s more metastatic melanoma is the main cause of its high mortality. Among all organs, the lung is one of the most common distant metastatic sites of melanoma, and the mortality rate of melanoma lung metastasis is also very high. Elucidating the mechanisms involved in the pulmonary metastasis of cutaneous melanoma will not only help to provide possible explanations for its etiology and progression but may also help to provide potential new therapeutic targets for its treatment. Increasing evidence suggests that tumor-associated macrophages (TAMs) play an important regulatory role in the migration and metastasis of various malignant tumors. Tumor-targeted therapy, targeting tumor-associated macrophages is thus attracting attention, particularly for advanced tumors and metastatic tumors. However, the relevant role of tumor-associated macrophages in cutaneous melanoma lung metastasis is still unclear. This review will present an overview of the origin, classification, polarization, recruitment, regulation and targeting treatment of tumor-associated macrophages, as well as the soluble mediators involved in these processes and a summary of their possible role in lung metastasis from cutaneous malignant melanoma. This review particularly aims to provide insight into mechanisms and potential therapeutic targets to readers, interested in pulmonary metastasis melanoma.

show abstract

Bone marrow/bone pre-metastatic niche for breast cancer cells colonization: The role of mesenchymal stromal cells

Cited by 26 publications

References 178 publications

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Pleiotropic Impacts on Breast Cancer Occurrence, Development, and Therapy

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Pleiotropic Impacts on Breast Cancer Occurrence, Development, and Therapy

Mesenchymal Stromal Cell-Derived Extracellular Vesicles as Biological Carriers for Drug Delivery in Cancer Therapy

The role of tumor-associated macrophages and soluble mediators in pulmonary metastatic melanoma

Contact Info

Product

Resources

About